Merck shares were up slightly on Wednesday after the pharma giant gave another key update for its KEYTRUDA line. The firm announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, in…
Pfizer reported mixed quarterly results before the markets opened on Tuesday and shares retreated in the premarket.
Melinta Therapeutics shares dropped on Monday despite the company announcing positive top-line results from its Phase 3 trial of Baxdela (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia.
Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
Dicerna Pharmaceuticals and Eli Lilly are partnering up in a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and…
Gilead shares retreated on Friday after it reported mixed third-quarter financial results late on Thursday.
The October 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Pharmaceutical maker Merck beat adjusted earnings estimates but missed slightly on revenues when it reported Q3 results Thursday morning. Investors responded positively, however.
The October 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
These four top pharmaceutical companies have longstanding franchises with huge sales and revenues, and their dividend-paying stocks look like outstanding choices for worried investors to consider now.
A large new study released today shows that American children fall short of the amount of exercise they need each day. The figures vary by both geography and type of exercise.
Alexion Pharmaceuticals reported better-than-expected quarterly results before the markets opened on Wednesday.
Biopharmaceutical company Orchard RX is offering more than 13 million shares in an initial public offering valued up to more than $245 million.
Pfizer, in collaboration with Bain Capital, announced the creation of Cerevel Therapeutics, a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system.
Proteostasis Therapeutics shares pulled back on Tuesday after the company announced that it would be conducting a secondary offering.
